Background. Astroblastomas (ABs) are rare glial tumors showing overlapping features with astrocytomas, ependymomas, and sometimes other glial neoplasms, and may be challenging to diagnose. Methods. We examined clinical, histopathological, and molecular features in 28 archival formalin-fixed, paraffinembedded AB cases and performed survival analyses using Cox proportional hazards and Kaplan-Meier methods. Results. Unlike ependymomas and angiocentric gliomas, ABs demonstrate abundant distinctive astroblastic pseudorosettes and are usually Olig2 immunopositive. They also frequently exhibit rhabdoid cells, multinucleated cells, and eosinophilic granular material. They retain immunoreactivity to alpha thalassemia/mental retardation syndrome X-linked, are immunonegative to isocitrate dehydrogenase-1 R132H mutation, and only occasionally show MGMT promoter hypermethylation differentiating them from many diffuse gliomas. Like pleomorphic xanthoastrocytoma, ganglioglioma, supratentorial pilocytic astrocytoma, and other predominantly cortical-based glial tumors, ABs often harbor the BRAF V600E mutation, present in 38% of cases tested (n = 21), further distinguishing those tumors from ependymomas and angiocentric gliomas. Factors correlating with longer patient survival included age less than 30 years, female gender, absent BRAF V600E , and mitotic index less than 5 mitoses/10 highpower fields; however, only the latter was significant by Cox and Kaplan-Meier analyses (n = 24; P = .024 and .012, respectively). This mitotic cutoff is therefore currently the best criterion to stratify tumors into low-grade ABs and higher-grade anaplastic ABs.
Astroblastomas (ABs) are rare glial tumors first described in the 1920s. 1,2 They most frequently involve the cerebral cortex of children and young adults [1] [2] [3] [4] [5] [6] [7] and rarely the ventricles, cerebellum, brainstem, or spinal cord. [7] [8] [9] Their characteristic histopathological feature is the astroblastic pseudorosette. 1 These glial fibrillary acidic protein (GFAP)-immunoreactive structures consist of monopolar or less commonly cuboidal tumor cells radially oriented around a central blood vessel and thus represent a type of perivascular pseudorosette (Fig. 1) . Astroblastomas are separated into low-grade or "well-differentiated" tumors, demonstrating low proliferative activity, and high-grade tumors exhibiting conspicuous mitotic activity and/or necrosis. 2, 3 Low-grade ABs are often cured by gross total resection, while high-grade ABs may be associated with relatively short survival. [2] [3] [4] 10, 11 A few low-grade ABs have been reported to be clinically aggressive, however, and some high-grade AB patients have experienced prolonged survival with aggressive surgical and/or adjuvant therapy. 4, 6, [11] [12] [13] [14] Because of this variable clinical behavior, ABs have yet to be assigned World Health Organization (WHO) tumor grades, 3 and histological parameters distinguishing clinically benign ABs from aggressive examples are not well defined. Furthermore, there appears to be a relatively high degree of discordance among neuropathologists in making the diagnosis of AB.
In this study we reviewed the clinical and histological features of a series of 28 ABs and tested for contemporary glioma biomarkers. The latter included Ki-67 protein labeling index, isocitrate dehydrogenase 1 (IDH1) R132H mutant protein expression, alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein expression, SWItch/Sucrose NonFermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1/ INI1) protein expression, O 6 -methylguanine methyltransferase (MGMT) gene promoter hypermethylation, and the V600E mutation of the B-Raf serine-threonine kinase gene (BRAF V600E ). We then performed statistical analyses to test which of these parameters correlated with patient survival.
Methods

Histopathology
Studies were performed under institutional review board approved protocols. Cases diagnosed as AB at tertiary care centers were centrally reviewed by the first 2 authors. Histological criteria for inclusion in the study were as follows: (i) the presence of astroblastic pseudorosettes, occurring at least focally back to back or nearly so, and comprising at least 50% of the specimen; (ii) cuboidal, columnar, or tapered perivascular cellular processes, occasionally ending in broad endfeet; and (iii) absence of definitive features of other CNS neoplasms. Immunohistochemistry for Ki-67, ATRX, Olig2, IDH1 R132H , and SMARCB1/INI1 was performed using standard methods as described in the Supplementary material. Mitotic count and the Ki-67 labeling index were determined in the most actively proliferating areas of tumors.
MGMT Promoter Methylation
DNA (250 ng) extracted from formalin-fixed, paraffinembedded tissues (Qiagen QIAamp DNA Micro Kit) was bisulfite treated (EZ DNA Methylation Kit, Zymo Research) and 3 µL was amplified in a 50 µL reaction (Qiagen HotStar DNA Polymerase Kit). Primers spanning 5 cytosine-phosphate-guanine (CpG) islands in region +17 to +39 of the MGMT gene, included in the CpG MGMT Kit (Qiagen), were annealed at 55°C for PCR. Pyrosequencing was performed with 30 µL of amplicon using the PyroMark Q96 ID (Qiagen). The threshold value for hypermethylation established at The Ohio State University is when the average methylation rate of 5 CpG islands is equal to or greater than 10%.
BRAF V600E Mutation Analysis
Somatic mutation analyses for BRAF V600E were performed using a single nucleotide extension assay (SNaPshot Multiplex System, Life Technologies) and results were confirmed with Sanger sequencing.
Statistics
Data were analyzed using SPSS statistical analysis software v20 (IBM). Univariate analyses were conducted using Fisher's exact test, and Pearson chi-square was used for categorical data. Student's independent sample t-test and the Mann-Whitney U-test were employed for continuous data. Survival analyses were conducted using KaplanMeier (KM) (Mantel-Cox log rank) and Cox proportional
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hazards regression analyses. Cutoff values for continuous data (age, Ki-67 labeling index, and mitotic index) were determined using the receiver operating characteristic (ROC) method. All tests were 2-sided and a P-value of .05 was considered statistically significant.
Results
Patients and Histology
Twenty-seven AB cases diagnosed in university hospitals from 1992 to 2015 and 3 older archival cases from the former Armed Forces Institute of Pathology were histologically reviewed. One of the latter cases showed significant overlapping features with pilocytic astrocytoma, and one of the former was most consistent with glioblastoma. The remaining 28 cases met our inclusion criteria for AB and were further studied. Patient age at presentation ranged from 4 to 71 years ( Supplementary Fig. S1 ). Average and median ages were 28 and 22.5 years, respectively. The observed age distribution of AB in this series thus confirms its pediatric and young adult predominance; however, patients also presented in the fifth, sixth, and eighth decades (14.3%, 10.7%, and 3.6%, respectively).
Seventeen patients were female and 11 were male, corresponding to a ratio of 1.5:1 ( Supplementary Fig. S1 ). This was less than the previously reported ratios of 2:1 to 11:1 5, 6 but similar to the 1.3:1 ratio found in a prior histopathological study of 23 cases. 4 An epidemiologic study of 239 AB cases in the Surveillance, Epidemiology, and End Results cancer registry, however, revealed an equal male-to-female ratio. 15 Nonetheless, any female predominance of AB is likely lower than previously thought.Tumor location data were available for the 26 cases diagnosed from 1992 to 2015 (Table 1) . Thirteen tumors occurred in the left cerebral The patient is deceased; however, the length of survival could not be ascertained.
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hemisphere, 12 in the right hemisphere, and 1 in the cervical spinal cord. Ten cases involved the parietal lobe, 8 were in the temporal lobe, 5 the occipital lobe, and 5 the frontal lobe. One case was described only as left parasagittal. Of those presenting in more than one lobe, 2 were frontoparietal, 2 were parietooccipital, and 1 was temporooccipital. The parietal and temporal lobes were thus the most common regions involved by AB in this series.
Tumors originally diagnosed as high-grade (n = 19) were twice as common as low-grade examples (n = 9). A designation of "high-grade" was made based on mitotic activity ≥3/10 high-power fields (hpf) ( (6/28) showed necrosis and no case exhibiting necrosis (16/28) was without detectable mitotic activity. Five cases with mitotic counts ranging from 2 to 6/10 hpf, however, lacked necrosis.
Two major histological patterns of astroblastic pseudorosettes were identified: those exhibiting columnar-like monopolar cells, varying from stout to tall, frequently with outwardly expanded broad endfeet palisading around blood vessels ( Tumor cell nuclei were generally round and relatively uniform, often vesicular, and with a small but distinct nucleolus. In some cells the chromatin was evenly distributed and finely granular, similar to that of ependymomas. Several cases exhibited occasional vacuole-like intranuclear pseudoinclusions (Figs 2 G, H; 3 I). Rarely, large atypical nuclei resembling those seen in pleomorphic xanthoastrocytoma (PXA) were observed (Fig. 3 I) .
Gemistocytic and rhabdoid cells were frequently found within cellular areas between astroblastic pseudorosettes (Supplementary Table S1 Table  S1 ). Additionally, small primitive-appearing cells with dense chromatin were present in 3 cases (Fig. 2 J, K, N, T) , all of which showed increased mitotic activity (5 to 8/10 hpf). Rare large bubbly cells (Fig. 3 C and I ) and oligodendroglioma-like cells (Fig. 2 H) were each also noted in 3 cases. Calcifications were occasionally present, and one case showed ossification. Notably, most of these variant features have been previously described in individual AB case reports. 2, 11, 14, 16 Surprisingly, eosinophilic granular bodies (EGBs) were identified in several cases (Supplementary Table S1 ). These were often relatively pale and finely granular ( Fig. 3 B) ; however, some were brightly eosinophilic and coarsely granular, like classic EGBs (Fig. 2 F) . Occasionally, eosinophilic granular material appeared to be extracellular (Fig. 2  R) or was present within gemistocytic cells (Figs 2 L; 3 I, J, M). Intracellular eosinophilic granular material has also been observed in granular cell astrocytomas 17, 18 and oligodendrogliomas. 19, 20 These structures were thought to represent tiny Rosenthal fibers in some cases 18, 20 and autophagic lysosome-related structures in others. 17, 19 In the latter case, their presence may suggest autophagic degeneration, possibly partially explaining the often cystic neuroimaging features of ABs. 5 Interestingly, other tumors commonly exhibiting EGBs are often cystic (ie, pilocytic astrocytomas, gangliogliomas, and PXAs).
Astroblastomas also occasionally demonstrated pale homogenous hyaline spherical bodies not obviously associated with a cellular nucleus. Many of these appeared membrane bound and may represent cross sections of cellular inclusions (Figs 2 G, H, L; 3 D, N). The nature of these hyaline bodies and extent that they may or may not represent the same process or be related to rhabdoid cell inclusions or eosinophilic granular material are unknown and require further study.
As described by Bailey and Bucy in their 1930 description of AB, 1 multinucleated cells and lymphocytic infiltrates were frequently observed (Supplementary Table S1 ). The latter were usually perivascular and were present in ∼60% of our cases (Figs 2 P, Q; 3 A). Multinucleated tumor cells were larger than surrounding tumor cells, but not as large as typical glioma "giant cells" (Fig. 2 G, H 
BRAF V600E Mutation Analysis
BRAF V600E mutation was found in 8 of 21 cases (38%) in which adequate DNA was available (Table 1 ). Seven occurred in female patients ranging from 12 to 38 years of age. The single male patient with a mutation presented at 33 years of age. BRAF V600E mutant cases were thus clustered in a narrow age group comprising the second to early fourth decades of life (mean 25 y) ( Supplementary  Fig. S1 ). In contrast, the frequency of BRAF V600E mutations in gangliogliomas was reported to be greatest in patients presenting in the first decade, gradually decreasing thereafter. 21 The patient age distribution of BRAF V600E mutations observed for AB more closely resembles that of PXA. 22 All BRAF V600E positive AB cases showed mitotic activity, demonstrated rhabdoid cells, and showed at least a focal papillary-like structure (Table 1, Fig. 3 ; Supplementary  Table S1 ). Most but not all BRAF V600E negative tumors also Table S1 ). Similar to ganglioglioma, 21 the association of lymphocytic infiltrates with BRAF V600E mutation in ABs was statistically significant (Fisher's exact test, P = .018). Interestingly, lymphocytic infiltrates are enriched in glioblastomas associated with neurofibromin 1 mutations. 23 Both BRAF V600E and neurofibromin 1 mutations may activate mitogen-activated protein kinase signaling. 24 Hence, it is possible that trophic factors associated with gliomas with mitogen-activated protein kinase activation, such as interleukin-6, 25 may recruit lymphocytes.
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MGMT Promoter Methylation
MGMT promoter hypermethylation was found in only 12% of cases tested, similar to the 18% rate reported in a series of 11 PXAs. 26 It was present in a 38-year-old woman, a 44-year-old woman, and a 33-year-old man (Table 1) . Its absence in younger AB patients may be analogous to the tendency to see MGMT promoter hypermethylation only in adult cases of diffuse astrocytoma. 27 Two cases with MGMT promoter hypermethylation also harbored the BRAF V600E mutation.
Olig2, ATRX, SMARCB1/INI1, and IDH1 R132H Immunohistochemistry
Twenty-three of 25 (92%) tumors tested were Olig2 positive (Table 1 ). Nuclear staining intensity was occasionally weak and overall more variable than in oligodendrogliomas (Fig. 2 U) . No tumor showed loss of nuclear ATRX protein immunoreactivity when appropriate internal control immunoreactivity was present (n = 23) ( Table 1) . SMARCB1/INI1 protein immunostaining was intact and IDH1 R132H mutant protein immunostaining was negative 
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in all cases tested (n = 25). A recent independent study also reported no IDH1 mutations in AB. 28 
Survival Analysis
Follow-up survival data were available for 25 cases (Table 1) . Mean and median follow-up were equal at 7.7 years (92 mo). Sixteen AB patients were alive at the time of last follow-up and 9 had died. Patients 30 years of age or less and female patients tended to survive longer than older or male patients (Fig. 4 A and B, Table 2 ). Eightytwo percent of female AB patients for whom survival information was available for at least 5 years from diagnosis (9/11 cases) were alive at 5 years, while only 44% of male patients (4/9 cases) were alive at 5 years. The overall Cox hazard ratio for male gender was 2.2; however, this did not reach statistical significance (P = .25), nor did it in KM analysis (P = .24; Table 2 A, Fig. 4 B) .
Patients originally diagnosed with histologically highgrade AB also tended to show decreased survival compared with low-grade AB, but this was not statistically significant by KM analysis (P = .11; Table 2 A, Fig. 4 C) . Cox analysis revealed an approximately 4.8-fold risk of death in high-grade AB patients; however, this was also not significant (Table 2 B) .
Next we tested for a possible association of Ki-67 labeling index with survival. A Ki-67 labeling index of 4% was determined to be the best cutoff using the ROC method. Although the KM plot suggests better survival of patients with Ki-67 labeling indices of 4% or less, this was not statistically significant (Table 2 ; Supplementary Fig. S2A ). The presence of necrosis or the BRAF V600E mutation were both associated with an approximately 2-fold increased risk of death, but again neither was statistically significant (Table 2 ; Supplementary Fig. S2B, C) .
Mitotic index data were available for 27 cases (Table 1) . Mean and median mitotic counts were 6.4/10 hpf and 3/10 hpf, respectively. The ROC method yielded a cutoff value of 4 mitoses/10 hpf. Five-year survival data were available for 15 of the 18 patients showing 4 or fewer mitoses per 10 hpf, of whom 3 had died, correlating with a 5-year overall survival rate of 80.0%. Seven of 9 patients demonstrating 5 or more mitoses/10 hpf had available 5-year survival data, of whom 5 had died. The 5-year overall survival for this group was only 28.6%. These differences were statistically significant by both KM analysis (P = .012; Fig. 4 D) and Cox proportional hazards analysis, where 5 or more mitoses/10 hpf was associated with a 5.4-fold increased risk of patient death (P = .024; Table 2 ). After adjusting for BRAF V600E mutation, patients with a mitotic count of 5 or more were 9.4 times more likely to have died (P = .031; Table 2 B) .
Discussion
Histologically, AB is most often confused with ependymoma. 2, 3, 11, 29 Olig2 positivity, found in the majority of AB cases tested, however, appears to exclude most ependymomas. 30 Additionally, many ependymomas demonstrate true ependymal rosettes, which are generally not Indicated mitotic counts are from 10 high-power fields. χ 2 = chi square, df = degrees of freedom. Sample numbers (n) for each variable are the same as for the KM analyses above, df = degrees of freedom. a Hierarchical regression.
conspicuous in ABs (Fig. 1 F) . 11 Common histological features of AB described herein, which are usually absent in ependymoma, include frequent multinucleated cells, perivascular cells with nuclear clearing, eosinophilic granular material, lymphocytic infiltrates, rhabdoid cells, hyaline spherical bodies, and nuclear pseudoinclusions. These features are also usually absent in most diffuse gliomas, excluding glioblastoma, albeit some occur in pilocytic astrocytomas, gangliogliomas, and PXAs. The latter tumors, however, lack extensive astroblastic pseudorosettes and may show other features not found in AB, such as classic Rosenthal fibers, ganglion cells, bipolar spindle cells, or marked pleomorphism. Unlike other AB cases, case 22 infiltrated the perivascular spaces of surrounding brain and showed subpial aggregation, mimicking angiocentric glioma (AG). Common histological features of AB described above, however, are absent in AG. Unlike ABs, AGs by definition contain bipolar cells with elongated nuclei and usually lack detectable mitotic activity. 33, 34 Furthermore, in addition to radially oriented monopolar perivascular cells as seen in ABs and ependymomas, AGs also show circumferentially and longitudinally oriented perivascular growth patterns, which are absent in AB. Finally, AGs have been reported to be Olig2 negative 31, 32 and lack BRAF V600E mutations or the vascular hyalinization commonly seen in AB. [33] [34] [35] Rare reported cases of AG with astroblastoma-like features and/or increased mitotic activity 34, 36 should thus be reexamined, immunostained for Olig2, and tested for BRAF mutations.
Three AB cases exhibited cells resembling oligodendrocytes. The absence of 1p/19q loss of heterozygosity or IDH1/2 mutations rules out oligodendroglioma. The latter also excludes some diffuse astrocytomas and secondary glioblastomas, 37 while ATRX positivity eliminates a subset of astrocytomas and rare ATRX-negative glioblastomas. 38 SMARCB1/INI1 immunopositivity, on the other hand, rules out most atypical teratoid/rhabdoid tumors and cribriform neuroepithelial tumors. 39 Although this is the largest reported histopathological study of AB, statistical analyses related to survival are limited by the still relatively small number of cases and variable patient follow-up intervals resulting in censoring of some data. Furthermore, information regarding extent of surgical resection, tumor recurrence, and adjuvant therapies was not available for several cases and was not considered (available data are presented in Supplementary  Table S2) .
Nevertheless, some interesting patterns emerged. Patients younger than 30 years of age and females clearly appeared to live longer. Age is a known prognostic indicator for many brain neoplasms, and although variable for different tumor types, older patients generally do worse. 40 Better survival in female patients has been reported in CNS tumors overall, 41 and specifically in ependymoma, medulloblastoma, and glioblastoma. [40] [41] [42] Of all factors examined related to AB patient survival, only mitotic count was statistically significant, strongly implicating it as the most important histological correlate of tumor behavior. Among cases for which at least 5-year follow-up data were available, 80% of patients with a mitotic count of ≤4/10 hpf were alive at 5 years compared with 28.6% of patients with mitotic counts of 5/10 hpf or greater (Table 1) . Comparable 5-year survival rates reported for ependymomas are 73% for grade II tumors and 49% for grade III tumors. 41 The above overall 5-year survival rates for AB fit closely with WHO estimates that patients with grade II CNS tumors usually survive over 5 years and most with grade III tumors survive 2-3 years. 43 We therefore propose a mitotic count of 5/10 hpf or more as the critical criterion for identifying more aggressive higher-grade lesions, namely anaplastic astroblastomas. Application of this criterion resulted in the reclassification of 9 tumors originally diagnosed as high-grade AB to low-grade AB and changed the ratio of high-grade to low-grade tumors in this series from originally 2:1 to close to 1:1 (Table 1) . Thus, a possible overemphasis of mitotic counts of <5/hpf and/or the presence of necrosis and resultant overgrading of tumors may account for some reported cases of "high-grade" AB associated with prolonged survival. Additional studies encompassing larger series of AB patients, including data on treatment and recurrences accompanied by expanded molecular profiles, are likely required to identify predictors of clinical behavior that would permit further histopathological or molecular stratification of ABs.
The histogenesis of AB has been an ongoing debate. Authors have argued whether ABs are more biologically related to ependymomas or diffuse astrocytomas. 2, 11 Histological and molecular findings in this series suggest the answer is "neither. " BRAF V600E mutations have been reported in up to 66% of PXAs, 58% of gangliogliomas, 51% of dysembryoplastic neuroepithelial tumors, 43% of subependymal giant cell astrocytomas (SEGAs), and 33% of diencephalic and 13% of cerebral pilocytic astrocytomas. 21, 22, 44 They are present much less frequently in pediatric glioblastomas, 45 desmoplastic infantile astrocytomas/ gangliogliomas, 46 and adult astrocytomas 22, 45 and are absent in ependymomas. 22 Albeit nonspecific, EGBs and lymphocytic infiltrates are also common in gangliogliomas, PXAs, and pilocytic astrocytomas. Nuclear pseudoinclusions and multinucleated cells are common in PXA but are also nonspecific and occur in a wide range of glial tumors. Nevertheless, combined with the similar age distribution at clinical presentation and roughly similar frequency of BRAF V600E mutation and MGMT promoter hypermethylation, our findings suggest that AB and PXA may share a closely related histogenesis.
On a larger scale, all pediatric gliomas with BRAF V600E mutations may be ontologically related, as, with the exception of SEGA and diencephalic pilocytic astrocytoma, nearly all tend to manifest as superficial cortical lesions. Pertinently, SEGA and diencephalic pilocytic astrocytoma also involve gray matter. Indeed, some of these tumors have been hypothesized to belong to a group of developmentally related gliomas with variable glial and neuronal differentiation. 47 This is not to say that ABs and ependymomas are unrelated. Their shared tendency to form perivascular pseudorosettes and demonstrate epithelial-like histomorphological characteristics clearly suggests the contrary. It is possible that ABs arise from a common radial glia-derived precursor cell representing a branch point prior to definitive ependymal or glioneuronal differentiation. 11, 29, 48 Regardless, AB will likely remain a controversial diagnosis prior to its definitive molecular characterization,
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and should be carefully differentiated from ependymoma, and other possible BRAF V600E mutant lesions.
Although not statistically significant, we observed a trend for ABs with BRAF V600E to be associated with shorter patient survival ( Supplementary Fig. S2C ), consistent with that found for melanoma, colorectal carcinoma and papillary thyroid carcinoma. 49, 50 Interestingly, a recent study of PXAs with longterm follow-up found significantly better survival for tumors with the BRAF V600E mutation, when both low-grade and anaplastic PXAs were considered together. 51 Compounding these findings, however, was a higher frequency of BRAF V600E in low-grade PXAs. In contrast, BRAF V600E mutation was evenly distributed in low-grade and anaplastic ABs (based on mitotic index ≥5/10 hpf). Nevertheless, in select AB patients with BRAF V600E and only partially resectable or recurrent tumor, BRAF inhibitor therapy may represent a potential treatment option. 52 Similarly the presence of MGMT promoter hypermethylation may suggest rational use of alkylating agents, such as temozolomide. We therefore recommend BRAF mutational analysis and MGMT promoter methylation testing in all suspected AB cases.
Supplementary Material
Supplementary material is available online at NeuroOncology (http://neuro-oncology.oxfordjournals.org/).
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